Advances in Multiple Sclerosis Research-Series I

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Is...

Full description

Saved in:
Bibliographic Details
Other Authors: Matsoukas, John (Editor), Apostolopoulos, Vasso (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Subjects:
MS
EAE
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_68583
005 20210501
003 oapen
006 m o d
007 cr|mn|---annan
008 20210501s2021 xx |||||o ||| 0|eng d
020 |a books978-3-03943-948-5 
020 |a 9783039439478 
020 |a 9783039439485 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-03943-948-5  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Matsoukas, John  |4 edt 
700 1 |a Apostolopoulos, Vasso  |4 edt 
700 1 |a Matsoukas, John  |4 oth 
700 1 |a Apostolopoulos, Vasso  |4 oth 
245 1 0 |a Advances in Multiple Sclerosis Research-Series I 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (334 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a multiple sclerosis 
653 |a inflammation 
653 |a oxidative 
653 |a biomarker 
653 |a sample size 
653 |a autoimmune encephalitis 
653 |a plasma exchange 
653 |a autoimmunity 
653 |a immunotherapeutics 
653 |a clinical outcomes 
653 |a major depression 
653 |a bupropion 
653 |a S-adenosylmethionine 
653 |a vitamin D3 
653 |a yoga 
653 |a craniopharyngioma 
653 |a fractionated stereotactic radiation treatments 
653 |a sphenoid sinusitis 
653 |a cranial nerve-VI palsy 
653 |a autoimmune diseases 
653 |a immune thrombocytopenic purpura 
653 |a alemtuzumab 
653 |a antibodies against GluR3 peptide 
653 |a cognitive impairment 
653 |a diagnosis 
653 |a neuropsychological assessment 
653 |a short intracortical inhibition 
653 |a intracortical facilitation 
653 |a fampridine 
653 |a walking disability 
653 |a TSPAN32 
653 |a tetraspanins 
653 |a cellular immunity 
653 |a memory T cells 
653 |a tDCS 
653 |a neuroimaging 
653 |a positron emission tomography 
653 |a cerebral blood flow 
653 |a probiotics 
653 |a Streptococcus thermophilus 
653 |a ST285 
653 |a MBP83-99 peptide 
653 |a mannan 
653 |a immune modulation 
653 |a agonist peptide 
653 |a gut microbiome 
653 |a gut-brain axis 
653 |a metagenomics 
653 |a disease-modifying treatments 
653 |a MS 
653 |a vaccine 
653 |a immunomodulation 
653 |a carriers 
653 |a B cell receptor 
653 |a delivery methods 
653 |a immunotherapy 
653 |a monoclonal antibodies 
653 |a T cell receptor 
653 |a tolerance 
653 |a diagnostic markers 
653 |a immunoglobulins 
653 |a kappa 
653 |a free light chains 
653 |a antigen-specific immunotherapies 
653 |a tolerogenic vaccines 
653 |a tolerance induction 
653 |a central nervous system 
653 |a myelin peptides 
653 |a myelin basic protei 
653 |a proteolipid protein 
653 |a myelin oligodendrocyte glycoprotein 
653 |a nanotechnology 
653 |a drug delivery nanosystems 
653 |a lipids 
653 |a polymers 
653 |a vaccines 
653 |a nanoparticles 
653 |a antigen-specific immunotherapy 
653 |a experimental autoimmune encephalomyelitis 
653 |a neurodegeneration 
653 |a chloroquine 
653 |a EAE 
653 |a dendritic cells 
653 |a microglia 
653 |a astrocytes 
653 |a oligodendrocytes 
653 |a conformational analysis 
653 |a peptides 
653 |a altered peptide ligands 
653 |a NMR spectroscopy 
653 |a NOE-constraints 
653 |a molecular dynamic 
653 |a trimolecular complex 
653 |a Multiple Sclerosis 
653 |a early-onset 
653 |a adult-onset 
653 |a Human Leucocyte Antigens 
653 |a immunogenetics 
653 |a clinical phenotype 
653 |a clinical outcome 
653 |a therapeutics 
653 |a antibody detection 
653 |a ELISA 
653 |a multivalency 
653 |a N-glucosylated peptide epitopes 
653 |a peptide 
653 |a conjugation 
653 |a MOG35-55 
653 |a Graphite/SiO2 electrode 
653 |a voltammetry 
653 |a HPLC 
653 |a MS drugs 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/3604  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/68583  |7 0  |z DOAB: description of the publication